TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31775686
Drug: Direct Observed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct Observed Therapy (DOT) for SP administration
Study: 28267474
Drug: Azimilide 75
Normalized name: Azimilide
DrugBank: Azimilide (DB04957)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azimilide 75 mg daily
Study: 27852711
Drug: Medication treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication treatment (MT) plus percutaneous transluminal angioplasty and stenting (PTAS)
Study: 27852711
Drug: Medication treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication treatment (MT) alone
Study: 27852711
Drug: Medication treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication treatment (MT) plus PTAS
Study: 25118680
Drug: Cemented shaft
Normalized name: Cacao seed oil, fermented
DrugBank: Cocoa butter (DB11086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cemented shaft implants
Study: 23963102
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg/day plus Tolterodine 2 mg (twice a day)
Study: 23963102
Drug: Tolterodine 2
Normalized name: tolterodine 2 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine 2 mg (twice a day)
Study: 17445639
Drug: No medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medical treatment (control group)
Study: 8085623
Drug: Indomethacin 2
Normalized name: indomethacin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 2 mg/kg
Study: 23356392
Drug: 125 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 µg fluticasone dipropionate and 25 µg salmeterol, two actuations twice daily, by either separate or combination ICS/LABA inhalers
Study: 8128175
Drug: Cisapride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (5 mg three times daily)
Study: 8128175
Drug: Metoclopramide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (10 mg three times daily)
Study: 163937
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with 0.3 percent 'Neutralrot' eye drops and radiation with daylight lamp HPR 125 W.
Study: 163937
Drug: Intramuscular inoculation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular inoculation with Interferonogen.
Study: 26087637
Drug: diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: diclofenac sodium 100 mg/day
Study: 26087637
Drug: Alflutop injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alflutop injection 1 ml per day for 20 days, then 2 ml intraarticular twice weekly in the following month
Study: 26087637
Drug: diacerein (diaflex,
Approvals — FDA: no, EMA: no, PMDA: no
Description: diacerein (diaflex, 'Rompharm Company') 50 mg twice daily for 3 months
Study: 23921483
Drug: Chromium-enriched yeast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chromium-enriched yeast (100 μg daily for 2 weeks)
Study: 23921483
Drug: Chromium-enriched yeast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chromium-enriched yeast (200 μg daily for 6 weeks)
Study: 23921483
Drug: Chromium-enriched yeast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chromium-enriched yeast (100 μg and 200 μg daily)
Study: 21519733
Drug: Glutamine group
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine group (50 g L-glutamine, 400 mL evening drink and 200 mL 2 hours before anesthesia)
Study: 21519733
Drug: Carbohydrate group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate group (12.5% maltodextrine, 400 mL evening drink and 200 mL 2 hours before anesthesia)
Study: 21519733
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (water, 400 mL evening drink and 200 mL 2 hours before anesthesia)
Study: 11724442
Drug: Antibodies to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies to IFN-gamma
Study: 11724442
Drug: Antibodies to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies to TNF-alpha
Study: 8492200
Drug: Ibuprofen-codeine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen-codeine (400 mg ibuprofen + 60 mg codeine)
Study: 20597358
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (received one session of psycho-education about self-complexity and kept daily records for one week)
Study: 17121048
Drug: Acupuncture in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture in Siguan points combined with intravenous midazolam injection
Study: 17121048
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam injection
Study: 12541156
Drug: DCLHb (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCLHb (up to 1000 ml of a 10% diaspirin cross‐linked hemoglobin solution)
Study: 8445202
Drug: Methylprednisolone (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (initial bolus of 30 mg/kg followed by infusion of 5.4 mg/kg/h over 23 hours)
Study: 3528240
Drug: Systemic antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antibiotics plus elastic support bandages
Study: 29550766
Drug: Secukinumab 300
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 300 mg with loading dose (LD)
Study: 29550766
Drug: Secukinumab 150
Normalized name: secukinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 150 mg with loading dose (LD)
Study: 29550766
Drug: Secukinumab 150
Normalized name: secukinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 150 mg without loading dose (LD)
Study: 24504006
Drug: Valacyclovir 500
Normalized name: valacyclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir 500 mg twice-daily for 12 months
Study: 22146609
Drug: Conventional walking
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional walking treatment (CWT)
Study: 16243131
Drug: All light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: All light doses (70, 100, 140 J/cm2)
Study: 26197801
Drug: Blended learning
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blended learning approach (combination of face-to-face and online/mobile learning)
Study: 16890114
Drug: EC-MPS 1,080
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC-MPS 1,080 mg twice daily
Study: 16890114
Drug: MMF 1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF 1,500 mg twice daily
Study: 15292101
Drug: 4 LNG
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 LNG rods (75 mg each) followed by 500 mg of TU by IM injection every 8 weeks for 24 weeks (Group I)
Study: 15292101
Drug: 4 LNG
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 LNG implants followed by 1000 mg of TU by IM injection every 8 weeks for 24 weeks (Group II)
Study: 15292101
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of TU by IM injection every 8 weeks for 24 weeks (Group III)
Study: 9444444
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of lubeluzole (1-hour intravenous infusion)
Study: 9444444
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of lubeluzole (1-hour intravenous infusion)
Study: 9444444
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of lubeluzole (1-hour intravenous infusion)
Study: 9444444
Drug: Lubeluzole (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubeluzole (various doses)
Study: 29956042
Drug: Optimum post-infarction
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimum post-infarction treatment (Control group)
Study: 18599019
Drug: Topical ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ketorolac 0.4% plus prednisolone acetate 1% QID
Study: 18599019
Drug: Topical prednisolone
Normalized name: prednisolone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical prednisolone acetate 1% QID alone
Study: 10699908
Drug: Weekly continuation
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly continuation chemotherapy with rotating pairs of drugs (teniposide and cytarabine, vincristine and cyclophosphamide) with repeated reinduction with PVDA
Study: 10699908
Drug: Weekly continuation
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly continuation chemotherapy with rotating pairs of drugs (teniposide and cytarabine, vincristine and cyclophosphamide) without repeated reinduction with PVDA
Study: 10699908
Drug: Allogeneic bone
Normalized name: Human allogeneic bone marrow derived osteoblastic cells
DrugBank: Human allogeneic bone marrow derived osteoblastic cells (DB17890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic bone marrow transplantation (BMT) instead of continued chemotherapy
Study: 9347435
Drug: Mivacurium 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium 0.3 mg/kg
Study: 29173822
Drug: Clinical and
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical and home-based physical activity program (PAP) and simple lymphatic drainage (SLD), administered twice a week for six weeks.
Study: 25493545
Drug: CC (Combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC (Combination Condition)
Study: 20229199
Drug: Pamidronate (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (30 mg disodium pamidronate, n=24)
Study: 20229199
Drug: Pamidronate (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (30 mg disodium pamidronate)
Study: 16490472
Drug: Nonselective NSAIDs
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonselective NSAIDs (diclofenac 50 mg BID or naproxen 500 mg BID)
Study: 14988517
Drug: Extract of
Normalized name: Extract of tomato
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extract of Perilla frutescens enriched for rosmarinic acid (200 mg)
Study: 14988517
Drug: Extract of
Normalized name: Extract of tomato
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extract of Perilla frutescens enriched for rosmarinic acid (50 mg)
Study: 14988517
Drug: Extract of
Normalized name: Extract of tomato
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extract of Perilla frutescens enriched for rosmarinic acid (200 mg and 50 mg combined)
Study: 10751780
Drug: Local delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local delivery of heparin at 40- or 100-psi infusion pressure
Study: 10751780
Drug: Local delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local delivery of heparin at 100 psi
Study: 10751780
Drug: Local delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local delivery of heparin
Study: 8453959
Drug: New inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: New inhalation spacer device (Rondo) with salbutamol (Salbuvent)
Study: 8453959
Drug: Salbutamol (Salbuvent)
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol (Salbuvent) with conventional metered dose actuator
Study: 8453959
Drug: New inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: New inhalation spacer device (Rondo)
Study: 3518775
Drug: Theophylline (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (single dose, levels greater than 10 micrograms ml‐1)
Study: 30035566
Drug: Doing everyday
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doing everyday solitary activities (e.g., reading, watching TV)
Study: 29067598
Drug: Religious Cognitive
Normalized name: red delicious apple allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Religious Cognitive Behavioral Therapy (R-CBT)
Study: 29067598
Drug: Conventional Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Cognitive Behavioral Therapy (C-CBT)
Study: 25299079
Drug: Remifentanil preconditioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil preconditioning (R3 group, 1.8 μg·kg(‐1)·min(‐1))
Study: 23097240
Drug: Ketoconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (200 mg b.i.d. for 6 days)
Study: 23097240
Drug: Safinamide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safinamide (100 mg single dose)
Study: 20403374
Drug: No-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment control (n=49)
Study: 18936500
Drug: Sildenafil (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (20 mg three times daily, titrated to 40 mg and 80 mg as tolerated)
Study: 9821026
Drug: Out-patient treatment
Normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Out-patient treatment with low molecular weight heparin and oral anticoagulants, with daily attendance at the out-patient clinic.
Study: 7644189
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for vasovagal syncope
Study: 2504118
Drug: Mannitol cardioplegic
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mannitol cardioplegic solution (59.8 mmol/L)
Study: 1932652
Drug: Standard cardioplegic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cardioplegic solution
Study: 2504118
Drug: Mannitol cardioplegic
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mannitol cardioplegic solution
Study: 197443
Drug: ACTH4-10 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACTH4-10 (60 mg)
Study: 30229989
Drug: Stable IS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable IS monotherapy 1 year after transplantation
Study: 28178149
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of peripheral nerve block and general anesthesia (NB + GA)
Study: 21771098
Drug: Hydrocortisone 1%
Normalized name: HYDROCORTISONE 1% OINT
DrugBank: Hydrocortisone acetate (DB14539)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrocortisone 1% cream (HCT) applied twice daily for 4 weeks
Study: 21771098
Drug: Hydrocortisone 1%
Normalized name: HYDROCORTISONE 1% OINT
DrugBank: Hydrocortisone acetate (DB14539)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrocortisone 1% cream (HCT)
Study: 21771098
Drug: Hydrocortisone 1%
Normalized name: HYDROCORTISONE 1% OINT
DrugBank: Hydrocortisone acetate (DB14539)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrocortisone 1% cream (HCT) and Pimecrolimus 1% cream (PIM)
Study: 20426883
Drug: Rimonabant (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimonabant (20 mg)
Study: 16816943
Drug: Lorazepam (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (0.02 mg/kg body weight)
Study: 7919671
Drug: Low-dose hydrocortisone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose hydrocortisone (10 mg/L) and heparin (500 U/L) added to peripheral intravenous fluid (feed A)
Study: 7919671
Drug: Peripheral intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral intravenous fluid without heparin and hydrocortisone (feed B)
Study: 2904523
Drug: 5% dextrose
Normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% dextrose solution (5.4 ml/h)
Study: 26956188
Drug: GLP-1 infusion
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 infusion (1.5 pmol·kg–1·min–1)
Study: 21599819
Drug: Raltegravir 400
Normalized name: raltegravir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 400 mg bid with tenofovir/emtricitabine
Study: 21599819
Drug: Raltegravir 400
Normalized name: raltegravir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 400 mg bid with optimized background therapy
Study: 21599819
Drug: Efavirenz 600
Normalized name: efavirenz 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz 600 mg at bedtime with tenofovir/emtricitabine
Study: 21599819
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with optimized background therapy
Study: 12230933
Drug: Caspofungin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin (50 mg/day)
Study: 10684216
Drug: Emoxipin (2-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emoxipin (2-week monotherapy)
Study: 218154
Drug: 3 percent
Normalized name: SALICYLIC ACID 3 g in 100 g TOPICAL GEL [Keralyt 3 PERCENT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 percent vidarabine applied topically six times daily for 7 days
Study: 7037982
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of Salmonella typhi strain Ty 21a oral vaccine (1‐8 X 10(9) live Ty 21a bacteria per dose)
Study: 7037982
Drug: Placebo (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (three doses)
Study: 22967171
Drug: Implants placed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implants placed in maxillary native bone (group A)
Study: 22967171
Drug: Implants placed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implants placed in sinus-grafted sites (group B)
Study: 22967171
Drug: Implants placed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implants placed in group B1 (simultaneous insertion)
Study: 22967171
Drug: Implants placed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implants placed in group B2 (6 months after sinus lift)
Study: 21774840
Drug: Quercetin-enriched cereal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin-enriched cereal bars (130 mg quercetin equivalents)
Study: 21774840
Drug: Quercetin powder-filled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin powder-filled hard capsules (130 mg quercetin equivalents)
Study: 21774840
Drug: Quercetin powder-filled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin powder-filled hard capsules
Study: 21774840
Drug: Quercetin-enriched cereal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin-enriched cereal bars and quercetin powder-filled hard capsules
Study: 17766567
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) group, 11-week duration
Study: 1967516
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg vecuronium
Study: 1967516
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg vecuronium
Study: 28975304
Drug: Oral cephalexin
Normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cephalexin 500 mg and metronidazole 500 mg every 8 hours for 48 hours
Study: 25799446
Drug: AH Plus®
Approvals — FDA: no, EMA: no, PMDA: no
Description: AH Plus® sealer with immediate post space preparation
Study: 25799446
Drug: AH Plus®
Approvals — FDA: no, EMA: no, PMDA: no
Description: AH Plus® sealer with delayed post space preparation
Study: 25799446
Drug: MTA Fillapex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTA Fillapex® sealer with immediate post space preparation
Study: 25799446
Drug: MTA Fillapex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTA Fillapex® sealer with delayed post space preparation
Study: 25799446
Drug: Positive control
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive control groups (no treatment)
Study: 25799446
Drug: Negative control
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative control groups (no treatment)
Study: 22906553
Drug: Ketamine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine at a psychotomimetic dose
Study: 19240251
Drug: GHRH and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH and GHRP-2 infusion
Study: 17976101
Drug: ICD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD therapy delivered to patients presenting with stable ventricular tachycardia (VT)
Study: 17976101
Drug: ICD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD therapy delivered to patients with ischemic etiology
Study: 17976101
Drug: ICD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD therapy delivered to patients with tiered therapy programmed ICDs
Study: 17976101
Drug: ICD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD therapy delivered to patients using beta-blockers
Study: 17976101
Drug: Time to
Normalized name: Overtime Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time to first appropriate therapy between first and second ICDs
Study: 14679381
Drug: E+ (sucrose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: E+ (sucrose, 100 g/l, 1672 kJ)
Study: 11887021
Drug: Daily mouthrinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily mouthrinse with triclosan-zinc for 8 weeks
Study: 11887021
Drug: 0.2% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% chlorhexidine spray for 2 weeks
Study: 10438868
Drug: Intranasal spray
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal spray vaccination with 15 micrograms of HA and 2 micrograms of HLT
Study: 10438868
Drug: Two nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two nasal spray vaccinations with 7.5 micrograms of HA with 1 microgram of HLT
Study: 10438868
Drug: Single spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single spray vaccination with 15 micrograms of HA and 2 micrograms of HLT
Study: 10438868
Drug: Parenteral virosomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral virosomal vaccine with 15 micrograms of HA without additional adjuvant
Study: 8658281
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pefloxacin (Abaktal) and clindamycin
Study: 2272604
Drug: Tolazamide (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolazamide (daily oral weight-adjusted)
Study: 7450653
Drug: Retard tablet
Normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retard tablet (enteric-coated)